Control-Based Imputation and Delta-Adjustment Stress Test for Missing Data Analysis in Longitudinal Clinical Trials

Statistics in Biopharmaceutical Research

Volumn 9, Issue 2, 2017, Pages 186-194

  Liu, G Frank ^a   Pang, Lei ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Longitudinal clinical trial; Missing data; Multiple imputation; Sensitivity analysis; Tipping point analysis

Indexed keywords

ANTIDEPRESSANT AGENT;

ANALYSIS OF COVARIANCE; ANALYSIS OF VARIANCE; ARTICLE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DATA ANALYSIS; DELTA ADJUSTMENT METHOD; EXERCISE TEST; EXTERNAL VALIDITY; HUMAN; MATHEMATICAL PARAMETERS; NORMAL DISTRIBUTION; NULL HYPOTHESIS; PROBABILITY; SAMPLE SIZE; SENSITIVITY ANALYSIS; STATISTICAL PARAMETERS;

EID: 85019269140     PISSN: None     EISSN: 19466315     Source Type: Journal    
DOI: 10.1080/19466315.2016.1256830     Document Type: Article

References (22)

1. Ayele, B. T., Lipkovich, I., Molenberghs, G., and Mallinckrodt, C. H., (2014), “A Multiple Imputation Based Approach to Sensitivity Analysis and Effectiveness Assessments in Longitudinal Clinical Trials,” Journal of Biopharmaceutical Statistics, 24, 211–228.
2. Carpenter, J. R., and Kenward, M. G., (2007), “Missing Data in Randomised Controlled Trials—A Practical Guide,” available at http://www.hta.nhs.uk/nihrmethodology/reports/1589.pdf
3. Carpenter, J. R., Roger, J. H., Cro, S., and Kenward, M. G., (2014), “Response to Comments by Seaman et al. on “Analysis of Longitudinal Trials with Protocol Deviation:A Framework for Relevant, Accessible Assumptions, and Inference Via Multiple Imputation,” Journal of Biopharmaceutical Statistics, 24, 1363–1369.
4. Carpenter, J. R., Roger, J. H., and Kenward, M. G., (2013), “Analysis of Longitudinal Trials with Protocol Deviation:A Framework for Relevant, Accessible Assumptions, and Inference Via Multiple Imputation,” Journal of Biopharmaceutical Statistics, 23, 1352–1371.
5. European Medicines Agency (2010), “Guideline on Missing Data in Confirmatory Clinical Trials,” available at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/09/WC500096793.pdf
6. Keller, M., Montgomery, S., Ball, W., Morrison, M., Snavely, D., Liu, G., Hargreaves, R., Hietala, J., Lines, C., Beebe, K., and Reines, R., (2006), “Lack of Efficacy of the Substance P (Neurokinin Receptor) Antagonist Aprepitant in the Treatment of Major Depressive Disorder,” Biological Psychiatry, 59, 216–223.
7. LaVange, L. M., and Permutt, T., (2015), “A Regulatory Perspective on Missing Data in the Aftermath of the NRC Report,” Statistics in Medicine, 35, 2853–2864.
8. Leuchs, A. K., Zinserling, J., Brandt, A., Wirtz, D., and Benda, N., (2015), “Choosing Appropriate Estimands in Clinical Trials,” Therapeutic Innovation & Regulatory Science, 49, 584–592.
9. Liu, G., and Pang, L., (2016), “On Analysis of Longitudinal Clinical Trials with Missing Data Using Reference-Based Imputation,” Journal of Biopharmaceutical Statistics, 26, 924–936.
10. Lu, K., (2014), “An Analytic Method for the Placebo-Based Pattern-Mixture Model,” Statistics in Medicine, 13, 103–109.
11. Mallinckrodt, C., Roger, J., Chuang-Stein, C., Molenberghs, G., Lane, P. W., O.Kelly, M., Ratitch, B., Xu, L., Gilbert, S., Mehrotra, D. V., Wolfinger, R., and Thijs, H., (2013), “Missing Data:Turning Guidance into Action,” Statistics in Biopharmaceutical Research, 5, 369–382.
12. Mallinckrodt, C. H., Lane, P. W., Schnell, D., Peng, Y., and Mancuso, J. P., (2008), “Recommendations for the Primary Analysis of Continuous Endpoints in Longitudinal Clinical Trials,” Drug Information Journal, 42, 305–319.
13. National Academy of Sciences (NRC) (2010), The Prevention and Treatment of Missing Data in Clinical Trials. Panel on Handling Missing Data in Clinical Trials. Committee on National Statistics, Division of Behavioral and Social Sciences and Education, Washington, DC:The National Academies Press.
14. O'Kelly, M., and Ratitch, B., (2014), Clinical Trials with Missing Data:A Guide for Practitioners, West Sussex:Wiley.
15. Permutt, T., (2015a), “A Taxonomy of Estimands for Regulatory Clinical Trials with Discontinuations,” Statistics in Medicine, 35, 2865–2875.
16. Permutt, T., (2015b), “Sensitivity Analysis for Missing Data in Regulatory Submissions,” Statistics in Medicine, 35, 2876–2879.
17. Ratitch, B., O'Kelly, M., and Tosiello, R., (2013), “Missing Data in Clinical Trials:From Clinical Assumptions to Statistical Analysis Using Pattern Mixture Models,” Pharmaceutical Statistics, 12, 337–347.
18. Robins, J. M., and Wang, N., (2000), “Inference for Imputation Estimators,” Biometrika, 87, 113–124.
19. Rubin, D., (1987), Multiple Imputation for Nonresponse in Surveys, New York:Wiley.
20. Seaman, S. R., White, I. R., and Leacy, F. P., (2014), “Comment on “Analysis of Longitudinal Trials with Protocol Deviation:A Framework for Relevant, Accessible Assumptions, and Inference via Multiple Imputation,” Journal of Biopharmaceutical Statistics, 24, 1358–1362.
21. Teshome, A. B., Lipkovich, I., Molenberghs, G., and Mallinckrodt, C. H., (2014), “A Multiple-Imputation-Based Approach to Sensitivity Analyses and Effectiveness Assessments in Longitudinal Clinical Trials,” Journal of Biopharmaceutical Statistics, 24, 211–228.
22. Yan, X., Lee, S., and Li, N., (2009), “Missing Data Handling Methods in Medical Device Clinical Trials,” Journal of Biopharmaceutical Statistics, 19, 1085–1098.